Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Diacomit
Diacomit 250 mg hard capsules · Abschnitt 4.5 · PDF-Seite 6
HOS-115338 · Präparat HOS-094267
- Cisapride, halofantrine, pimozide, quinidine, bepridil
Increased risk of cardiac arrhythmias and torsades de pointes/wave burst arrhythmia in particular.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cisapride (HOS-085610) bepridil (HOS-085612) halofantrine (HOS-085606) quinidine (HOS-085593) pimozide (HOS-085600)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-19T15:31:00Z · SHA-256 b075bfe26e1e2e48d4d17e44e4cfe0a1e4c38681d9170c43ecb8af51f184b9ab · Passage a91fcf12b70348667a561c14570c241d93f27c898aff1befbe29e1aa0dd7f386 · Zeichen 3874–4029 im Abschnitt
Wechselwirkungen · Diacomit
Diacomit 500 mg hard capsules · Abschnitt 4.5 · PDF-Seite 17
HOS-115388 · Präparat HOS-094267
- Cisapride, halofantrine, pimozide, quinidine, bepridil
Increased risk of cardiac arrhythmias and torsades de pointes/wave burst arrhythmia in particular.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cisapride (HOS-085610) bepridil (HOS-085612) halofantrine (HOS-085606) quinidine (HOS-085593) pimozide (HOS-085600)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-19T15:31:00Z · SHA-256 b075bfe26e1e2e48d4d17e44e4cfe0a1e4c38681d9170c43ecb8af51f184b9ab · Passage a91fcf12b70348667a561c14570c241d93f27c898aff1befbe29e1aa0dd7f386 · Zeichen 3872–4027 im Abschnitt
Wechselwirkungen · Diacomit
Diacomit 250 mg powder for oral suspension in sachet · Abschnitt 4.5 · PDF-Seite 28
HOS-115422 · Präparat HOS-094267
- Cisapride, halofantrine, pimozide, quinidine, bepridil
Increased risk of cardiac arrhythmias and torsades de pointes/wave burst arrhythmia in particular.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cisapride (HOS-085610) bepridil (HOS-085612) halofantrine (HOS-085606) quinidine (HOS-085593) pimozide (HOS-085600)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-19T15:31:00Z · SHA-256 b075bfe26e1e2e48d4d17e44e4cfe0a1e4c38681d9170c43ecb8af51f184b9ab · Passage a91fcf12b70348667a561c14570c241d93f27c898aff1befbe29e1aa0dd7f386 · Zeichen 3879–4034 im Abschnitt
Wechselwirkungen · Diacomit
Diacomit 500 mg powder for oral suspension in sachet · Abschnitt 4.5 · PDF-Seite 39
HOS-115457 · Präparat HOS-094267
- Cisapride, halofantrine, pimozide, quinidine, bepridil
Increased risk of cardiac arrhythmias and torsades de pointes/wave burst arrhythmia in particular.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cisapride (HOS-085610) bepridil (HOS-085612) halofantrine (HOS-085606) quinidine (HOS-085593) pimozide (HOS-085600)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-19T15:31:00Z · SHA-256 b075bfe26e1e2e48d4d17e44e4cfe0a1e4c38681d9170c43ecb8af51f184b9ab · Passage a91fcf12b70348667a561c14570c241d93f27c898aff1befbe29e1aa0dd7f386 · Zeichen 3879–4034 im Abschnitt
Wechselwirkungen · Exjade
EXJADE 90 mg film-coated tablets EXJADE 180 mg film-coated tablets EXJADE 360 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11
HOS-115539 · Präparat HOS-094307
Interaction with midazolam and other agents metabolised by CYP3A4
In a healthy volunteer study, the concomitant administration of deferasirox dispersible tablets and
midazolam (a CYP3A4 probe substrate) resulted in a decrease of midazolam exposure by 17% (90%
CI: 8% - 26%). In the clinical setting, this effect may be more pronounced. Therefore, due to a
possible decrease in efficacy, caution should be exercised when deferasirox is combined with
substances metabolised through CYP3A4 (e.g. ciclosporin, simvastatin, hormonal contraceptive
agents, bepridil, ergotamine).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): bepridil (HOS-085612) simvastatin (HOS-086158) ergotamine (HOS-086154) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T15:00:00Z · SHA-256 222a01b9b6233f96f99f56a88eeabc2cd5b2faff9038f592b1cc77a87d26915c · Passage f562040d78fbc96dc181c53f9b11f16693eafd9872950d615981f15ee56e9636 · Zeichen 1120–1692 im Abschnitt
Wechselwirkungen · Exjade
EXJADE 90 mg granules in sachet EXJADE 180 mg granules in sachet EXJADE 360 mg granules in sachet · Abschnitt 4.5 · PDF-Seite 31
HOS-115573 · Präparat HOS-094307
Interaction with midazolam and other agents metabolised by CYP3A4
In a healthy volunteer study, the concomitant administration of deferasirox dispersible tablets and
midazolam (a CYP3A4 probe substrate) resulted in a decrease of midazolam exposure by 17% (90%
CI: 8% - 26%). In the clinical setting, this effect may be more pronounced. Therefore, due to a
possible decrease in efficacy, caution should be exercised when deferasirox is combined with
substances metabolised through CYP3A4 (e.g. ciclosporin, simvastatin, hormonal contraceptive
agents, bepridil, ergotamine).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): bepridil (HOS-085612) simvastatin (HOS-086158) ergotamine (HOS-086154) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T15:00:00Z · SHA-256 222a01b9b6233f96f99f56a88eeabc2cd5b2faff9038f592b1cc77a87d26915c · Passage f562040d78fbc96dc181c53f9b11f16693eafd9872950d615981f15ee56e9636 · Zeichen 1263–1835 im Abschnitt
Gegenanzeigen · Prezista
PREZISTA 100 mg/ml oral suspension · Abschnitt 4.3 · PDF-Seite 6
HOS-116288 · Präparat HOS-094447
Darunavir boosted with either ritonavir or cobicistat inhibits the elimination of active substances that
are highly dependent on CYP3A for clearance, which results in increased exposure to the
co-administered medicinal product. Therefore, concomitant treatment with such medicinal products
for which elevated plasma concentrations are associated with serious and/or life-threatening events is
contraindicated (applies to darunavir boosted with either ritonavir or cobicistat). These active
substances include e.g.:
- alfuzosin
- amiodarone, bepridil, dronedarone, ivabradine, quinidine, ranolazine
- astemizole, terfenadine
- colchicine when used in patients with renal and/or hepatic impairment (see section 4.5)
- ergot derivatives (e.g. dihydroergotamine, ergometrine, ergotamine, methylergonovine)
- elbasvir/grazoprevir
- cisapride
- dapoxetine
- domperidone
- naloxegol
- lurasidone, pimozide, quetiapine, sertindole (see section 4.5)
- triazolam, midazolam administered orally (for caution on parenterally administered midazolam,
see section 4.5)
- sildenafil - when used for the treatment of pulmonary arterial hypertension, avanafil
- simvastatin, lovastatin, lomitapide (see section 4.5)
- ticagrelor (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) ticagrelor (HOS-112065) quetiapine (HOS-086150) elbasvir (HOS-108814) alfuzosin (HOS-086139) methylergonovine (HOS-086155) dronedarone (HOS-086144) cisapride (HOS-085610) lovastatin (HOS-086157) lomitapide (HOS-086160) cobicistat (HOS-088111) bepridil (HOS-085612) simvastatin (HOS-086158) quinidine (HOS-085593) domperidone (HOS-114656) avanafil (HOS-086161) naloxegol (HOS-109428) grazoprevir (HOS-108815) ivabradine (HOS-109426) pimozide (HOS-085600) colchicine (HOS-086147) astemizole (HOS-085608) sildenafil (HOS-086162) ergotamine (HOS-086154) ritonavir (HOS-084521) amiodarone (HOS-085596) terfenadine (HOS-085607) lurasidone (HOS-086148) ranolazine (HOS-086141) triazolam (HOS-086168) dihydroergotamine (HOS-086152) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage e2536d703754b5f39bebb9603c70a8d8759f7198e0666cec1af181c80f42d82c · Zeichen 1442–2753 im Abschnitt
Gegenanzeigen · Prezista
PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 49
HOS-116497 · Präparat HOS-094447
Co-administration of PREZISTA with low dose ritonavir, with active substances that are highly
dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with
serious and/or life-threatening events. These active substances include e.g.:
- alfuzosin
- amiodarone, bepridil, dronedarone, ivabradine, quinidine, ranolazine
- astemizole, terfenadine
- colchicine when used in patients with renal and/or hepatic impairment (see section 4.5)
- ergot derivatives (e.g. dihydroergotamine, ergometrine, ergotamine, methylergonovine)
- elbasvir/grazoprevir
- cisapride
- dapoxetine
- domperidone
- naloxegol
- lurasidone, pimozide, quetiapine, sertindole (see section 4.5)
- triazolam, midazolam administered orally (for caution on parenterally administered midazolam,
see section 4.5)
- sildenafil - when used for the treatment of pulmonary arterial hypertension, avanafil
- simvastatin, lovastatin and lomitapide (see section 4.5)
- ticagrelor (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) ticagrelor (HOS-112065) quetiapine (HOS-086150) elbasvir (HOS-108814) alfuzosin (HOS-086139) methylergonovine (HOS-086155) dronedarone (HOS-086144) cisapride (HOS-085610) lovastatin (HOS-086157) lomitapide (HOS-086160) bepridil (HOS-085612) simvastatin (HOS-086158) quinidine (HOS-085593) domperidone (HOS-114656) avanafil (HOS-086161) naloxegol (HOS-109428) grazoprevir (HOS-108815) ivabradine (HOS-109426) pimozide (HOS-085600) colchicine (HOS-086147) astemizole (HOS-085608) sildenafil (HOS-086162) ergotamine (HOS-086154) ritonavir (HOS-084521) amiodarone (HOS-085596) terfenadine (HOS-085607) lurasidone (HOS-086148) ranolazine (HOS-086141) triazolam (HOS-086168) dihydroergotamine (HOS-086152) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 6a604bfa742092630f592a37246ad3ddd261ae7ceba904108fadd195ca4e43c8 · Zeichen 481–1534 im Abschnitt
Gegenanzeigen · Prezista
PREZISTA 400 mg film-coated tablets PREZISTA 800 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 87
HOS-116580 · Präparat HOS-094447
Darunavir boosted with either ritonavir or cobicistat inhibits the elimination of active substances that
are highly dependent on CYP3A for clearance, which results in increased exposure to the
co-administered medicinal product. Therefore, concomitant treatment with such medicinal products
for which elevated plasma concentrations are associated with serious and/or life-threatening events is
contraindicated (applies to darunavir boosted with either ritonavir or cobicistat). These active
substances include e.g.:
- alfuzosin
- amiodarone, bepridil, dronedarone, ivabradine, quinidine, ranolazine
- astemizole, terfenadine
- colchicine when used in patients with renal and/or hepatic impairment (see section 4.5)
- ergot derivatives (e.g. dihydroergotamine, ergometrine, ergotamine, methylergonovine)
- elbasvir/grazoprevir
- cisapride
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): elbasvir (HOS-108814) alfuzosin (HOS-086139) methylergonovine (HOS-086155) dronedarone (HOS-086144) cisapride (HOS-085610) cobicistat (HOS-088111) bepridil (HOS-085612) quinidine (HOS-085593) grazoprevir (HOS-108815) ivabradine (HOS-109426) colchicine (HOS-086147) astemizole (HOS-085608) ergotamine (HOS-086154) ritonavir (HOS-084521) amiodarone (HOS-085596) terfenadine (HOS-085607) ranolazine (HOS-086141) dihydroergotamine (HOS-086152)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 986882b0b712a9a949916f43fb05836de98ea933859327e753cd9346903445da · Zeichen 1383–2254 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 100 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 15
HOS-116362 · Präparat HOS-094447
Amiodarone Co-administration of boosted
Bepridil PREZISTA and amiodarone,
Dronedarone bepridil, dronedarone, ivabradine,
Ivabradine quinidine, or ranolazine is
Quinidine contraindicated (see section 4.3).
Ranolazine
Digoxin digoxin AUC ↑ 61% Given that digoxin has a narrow
0.4 mg single dose digoxin Cmin ND therapeutic index, it is
digoxin Cmax ↑ 29% recommended that the lowest
(↑ digoxin from probable inhibition of possible dose of digoxin should
P-gp) initially be prescribed in case
digoxin is given to patients on
boosted PREZISTA therapy. The
digoxin dose should be carefully
titrated to obtain the desired
clinical effect while assessing the
overall clinical state of the subject.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dronedarone (HOS-086144) bepridil (HOS-085612) quinidine (HOS-085593) digoxin (HOS-086172) ivabradine (HOS-109426) amiodarone (HOS-085596) ranolazine (HOS-086141)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 0fca4263d4f5bc605a5ae9a42506a92581e4e87603747a8b6bef8d6ab34c7cfa · Zeichen 27581–29261 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 57
HOS-116517 · Präparat HOS-094447
Amiodarone PREZISTA co-administered with
Bepridil low dose ritonavir and
Dronedarone amiodarone, bepridil, dronedarone,
Ivabradine ivabradine, quinidine, or
Quinidine ranolazine is contraindicated (see
Ranolazine section 4.3).
Digoxin digoxin AUC ↑ 61% Given that digoxin has a narrow
0.4 mg single dose digoxin Cmin ND therapeutic index, it is
digoxin Cmax ↑ 29% recommended that the lowest
(↑ digoxin from probable inhibition of possible dose of digoxin should
P-gp) initially be prescribed in case
digoxin is given to patients on
darunavir/ritonavir therapy. The
digoxin dose should be carefully
titrated to obtain the desired
clinical effect while assessing the
overall clinical state of the subject.
ANTIBIOTIC
Clarithromycin clarithromycin AUC ↑ 57% Caution should be exercised when
500 mg twice daily
clarithromycin Cmin ↑ 174% clarithromycin is combined with
clarithromycin Cmax ↑ 26% PREZISTA co-administered with
#
darunavir AUC ↓ 13% low dose ritonavir.
#
darunavir Cmin ↑ 1%
# For patients with renal impairment
darunavir Cmax ↓ 17%
the Summary of Product
14-OH-clarithromycin concentrations
Characteristics for clarithromycin
were not detectable when combined with
should be consulted for the
PREZISTA/ritonavir.
recommended dose.
(↑ clarithromycin from CYP3A inhibition
and possible P-gp inhibition)
ANTICOAGULANT/PLATELET AGGREGATION INHIBITOR
Apixaban Not studied. Co-administration of The use of boosted PREZISTA
Rivaroxaban boosted PREZISTA with these with a direct oral anticoagulant
anticoagulants may increase (DOAC) that is metabolised by
concentrations of the anticoagulant. CYP3A4 and transported by P-gp
(CYP3A and/or P-gp inhibition) is not recommended as this may
lead to an increased bleeding risk.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dronedarone (HOS-086144) bepridil (HOS-085612) quinidine (HOS-085593) digoxin (HOS-086172) rivaroxaban (HOS-086236) lead (HOS-085592) clarithromycin (HOS-084517) apixaban (HOS-112091) ivabradine (HOS-109426) ritonavir (HOS-084521) amiodarone (HOS-085596) ranolazine (HOS-086141)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 227bb2dae3a2a6739ad7d75460b7010eb52122480b556e1f4afdf1e753dc6670 · Zeichen 21078–24599 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 400 mg film-coated tablets PREZISTA 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 97
HOS-116608 · Präparat HOS-094447
Amiodarone Co-administration of boosted
Bepridil PREZISTA and amiodarone,
Dronedarone bepridil, dronedarone, ivabradine,
Ivabradine quinidine, or ranolazine is
Quinidine contraindicated (see section 4.3).
Ranolazine
Digoxin digoxin AUC ↑ 61% Given that digoxin has a narrow
0.4 mg single dose digoxin Cmin ND therapeutic index, it is
digoxin Cmax ↑ 29% recommended that the lowest
(↑ digoxin from probable inhibition of possible dose of digoxin should
P-gp) initially be prescribed in case
digoxin is given to patients on
boosted PREZISTA therapy. The
digoxin dose should be carefully
titrated to obtain the desired
clinical effect while assessing the
overall clinical state of the subject.
ANTIBIOTIC
Clarithromycin clarithromycin AUC ↑ 57% Caution should be exercised when
500 mg twice daily
clarithromycin Cmin ↑ 174% clarithromycin is combined with
clarithromycin Cmax ↑ 26% boosted PREZISTA.
#
darunavir AUC ↓ 13%
#
darunavir Cmin ↑ 1% For patients with renal impairment
# the Summary of Product
darunavir Cmax ↓ 17%
Characteristics for clarithromycin
14-OH-clarithromycin concentrations
should be consulted for the
were not detectable when combined with
recommended dose.
PREZISTA/ritonavir.
(↑ clarithromycin from CYP3A inhibition
and possible P-gp inhibition)
ANTICOAGULANT/PLATELET AGGREGATION INHIBITOR
Apixaban Not studied. Co-administration of The use of boosted PREZISTA
Rivaroxaban boosted PREZISTA with these with a direct oral anticoagulant
anticoagulants may increase (DOAC) that is metabolised by
concentrations of the anticoagulant. CYP3A4 and transported by P-gp
(CYP3A and/or P-gp inhibition) is not recommended as this may
lead to an increased bleeding risk.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dronedarone (HOS-086144) bepridil (HOS-085612) quinidine (HOS-085593) digoxin (HOS-086172) rivaroxaban (HOS-086236) lead (HOS-085592) clarithromycin (HOS-084517) apixaban (HOS-112091) ivabradine (HOS-109426) ritonavir (HOS-084521) amiodarone (HOS-085596) ranolazine (HOS-086141)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage d32b19556a6cce04cd413a7b7e735b8fbe64621522b345e338c67799d622d39b · Zeichen 27793–31178 im Abschnitt
Wechselwirkungen · Sprycel
SPRYCEL 20 mg film-coated tablets SPRYCEL 50 mg film-coated tablets SPRYCEL 70 mg film-coated tablets SPRYCEL 80 mg film-coated tablets SPRYCEL 100 mg film-coated tablets SPRYCEL 140 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12
HOS-116690 · Präparat HOS-094467
Active substances that may have their plasma concentrations altered by dasatinib
Concomitant use of dasatinib and a CYP3A4 substrate may increase exposure to the CYP3A4
substrate. In a study in healthy subjects, a single 100 mg dose of dasatinib increased AUC and Cmax
exposure to simvastatin, a known CYP3A4 substrate, by 20 and 37% respectively. It cannot be
excluded that the effect is larger after multiple doses of dasatinib. Therefore, CYP3A4 substrates
known to have a narrow therapeutic index (e.g. astemizole, terfenadine, cisapride, pimozide,
quinidine, bepridil or ergot alkaloids [ergotamine, dihydroergotamine]) should be administered with
caution in patients receiving dasatinib (see section 4.4).
In vitro data indicate a potential risk for interaction with CYP2C8 substrates, such as glitazones.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cisapride (HOS-085610) bepridil (HOS-085612) simvastatin (HOS-086158) quinidine (HOS-085593) ergot alkaloids (HOS-108807) pimozide (HOS-085600) astemizole (HOS-085608) ergotamine (HOS-086154) terfenadine (HOS-085607) dihydroergotamine (HOS-086152)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-02T12:05:00Z · SHA-256 c065657005bf3f51d58db1cb5b29a1453d36e1fc897c0adb5e47ed684f07722e · Passage 33c05cfcb37f1e735202cb4b1a867414e511fc2e264773d7381a4ba9bdd45322 · Zeichen 3141–3952 im Abschnitt
Wechselwirkungen · Sprycel
SPRYCEL 10 mg/mL powder for oral suspension · Abschnitt 4.5 · PDF-Seite 48
HOS-116741 · Präparat HOS-094467
Active substances that may have their plasma concentrations altered by dasatinib
Concomitant use of dasatinib and a CYP3A4 substrate may increase exposure to the CYP3A4
substrate. In a study in healthy subjects, a single 100 mg dose of dasatinib increased AUC and Cmax
exposure to simvastatin, a known CYP3A4 substrate, by 20 and 37% respectively. It cannot be
excluded that the effect is larger after multiple doses of dasatinib. Therefore, CYP3A4 substrates
known to have a narrow therapeutic index (e.g. astemizole, terfenadine, cisapride, pimozide,
quinidine, bepridil or ergot alkaloids [ergotamine, dihydroergotamine]) should be administered with
caution in patients receiving dasatinib (see section 4.4).
In vitro data indicate a potential risk for interaction with CYP2C8 substrates, such as glitazones.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cisapride (HOS-085610) bepridil (HOS-085612) simvastatin (HOS-086158) quinidine (HOS-085593) ergot alkaloids (HOS-108807) pimozide (HOS-085600) astemizole (HOS-085608) ergotamine (HOS-086154) terfenadine (HOS-085607) dihydroergotamine (HOS-086152)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-02T12:05:00Z · SHA-256 c065657005bf3f51d58db1cb5b29a1453d36e1fc897c0adb5e47ed684f07722e · Passage 33c05cfcb37f1e735202cb4b1a867414e511fc2e264773d7381a4ba9bdd45322 · Zeichen 3142–3953 im Abschnitt
Wechselwirkungen · Intelence
INTELENCE 25 mg tablets INTELENCE 100 mg tablets INTELENCE 200 mg tablets · Abschnitt 4.5 · PDF-Seite 9–10
HOS-119738 · Präparat HOS-095005
9
Integrase Strand Transfer Inhibitors
Dolutegravir dolutegravir Etravirine significantly
50 mg once daily AUC ↓ 0.29 (0.26-0.34) reduced plasma
Cmin ↓ 0.12 (0.09-0.16) concentrations of
Cmax ↓ 0.48 (0.43-0.54) dolutegravir. The effect of
etravirine etravirine on dolutegravir
AUC ↔a plasma concentrations was
Cmin ↔a mitigated by
Cmax ↔a co-administration of
darunavir/ritonavir or
Dolutegravir + dolutegravir lopinavir/ritonavir, and is
darunavir/ritonavir AUC↓ 0.75 (0.69-0.81) expected to be mitigated by
50 mg once daily + Cmin ↓ 0.63 (0.52-0.77) atazanavir/ritonavir.
600/100 mg twice daily Cmax ↓ 0.88 (0.78-1.00)
etravirine INTELENCE should only be
AUC ↔a used with dolutegravir when
Cmin ↔a co-administered with
Cmax ↔a atazanavir/ritonavir,
darunavir/ritonavir, or
Dolutegravir + dolutegravir lopinavir/ritonavir. This
Lopinavir/ritonavir AUC↔ 1.11(1.02-1.20) combination can be used
50 mg once daily + Cmin ↑ 1.28 (1.13-1.45) without dose adjustment.
400/100 mg twice daily Cmax ↔ 1.07 (1.02-1.13)
etravirine
AUC ↔a
Cmin ↔a
Cmax ↔a
Raltegravir raltegravir INTELENCE and raltegravir
400 mg twice daily AUC ↓ 0.90 (0.68-1.18) can be used without dose
Cmin ↓ 0.66 (0.34-1.26) adjustments.
Cmax ↓ 0.89 (0.68-1.15)
etravirine
AUC ↔ 1.10 (1.03-1.16)
Cmin ↔ 1.17 (1.10-1.26)
Cmax ↔ 1.04 (0.97-1.12)
ANTIARRHYTHMICS
Digoxin digoxin INTELENCE and digoxin
0.5 mg single dose AUC ↑ 1.18 (0.90-1.56) can be used without dose
Cmin ND adjustments. It is
Cmax ↑ 1.19 (0.96-1.49) recommended that digoxin
levels be monitored when
digoxin is combined with
INTELENCE.
Amiodarone Not studied. INTELENCE is expected to Caution is warranted and
Bepridil decrease plasma concentrations of these therapeutic concentration
Disopyramide antiarrhythmics. monitoring, if available, is
Flecainide recommended for
Lidocaine (systemic) antiarrhythmics when
Mexiletine co-administered with
Propafenone INTELENCE.
Quinidine
ANTIBIOTICS
Azithromycin Not studied. Based on the biliary elimination INTELENCE and
pathway of azithromycin, no drug interactions azithromycin can be used
are expected between azithromycin and without dose adjustments.
INTELENCE.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lopinavir (HOS-086269) atazanavir (HOS-086180) propafenone (HOS-084530) flecainide (HOS-086203) lidocaine (HOS-108866) mexiletine (HOS-086341) bepridil (HOS-085612) dolutegravir (HOS-089992) quinidine (HOS-085593) digoxin (HOS-086172) azithromycin (HOS-088112) disopyramide (HOS-085595) darunavir (HOS-086181) raltegravir (HOS-086187) ritonavir (HOS-084521) amiodarone (HOS-085596)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-08-13T16:37:00Z · SHA-256 b6b2c3fd3d600c0f1fd17ddc8f6c1da50bcb8b2181089113d0397c5ec46864c4 · Passage 88eab8e7a4aadd0b0d68eee60d8b6c66c61e5724eefbfde8ea7e2649457e571e · Zeichen 11566–16118 im Abschnitt
Gegenanzeigen · Eurartesim
Eurartesim 160 mg/20 mg film-coated tablets. · Abschnitt 4.3 · PDF-Seite 4
HOS-123004 · Präparat HOS-095623
• Cisapride, droperidol, domperidone, bepridil, diphemanil, probucol, levomethadyl,
methadone, vinca alkaloids, arsenic trioxide.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): arsenic trioxide (HOS-109648) cisapride (HOS-085610) methadone (HOS-086198) bepridil (HOS-085612) droperidol (HOS-087801) domperidone (HOS-114656) diphemanil (HOS-085613) probucol (HOS-123007) levomethadyl (HOS-123008)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-04T13:58:00Z · SHA-256 dabfe6fde6102b83217e8e60df06f7976dca1a5f1a6c99e5db65545ad780075f · Passage 56ead3e4fd74fc66e7c5a56aeda1018da64014846db730724b0c2840337b898a · Zeichen 1760–1907 im Abschnitt
Gegenanzeigen · Eurartesim
Eurartesim 320 mg/40 mg film-coated tablets. · Abschnitt 4.3 · PDF-Seite 19
HOS-123063 · Präparat HOS-095623
• Cisapride, droperidol, domperidone, bepridil, diphemanil, probucol, levomethadyl,
methadone, vinca alkaloids, arsenic trioxide.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): arsenic trioxide (HOS-109648) cisapride (HOS-085610) methadone (HOS-086198) bepridil (HOS-085612) droperidol (HOS-087801) domperidone (HOS-114656) diphemanil (HOS-085613) probucol (HOS-123007) levomethadyl (HOS-123008)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-04T13:58:00Z · SHA-256 dabfe6fde6102b83217e8e60df06f7976dca1a5f1a6c99e5db65545ad780075f · Passage 6391a670f676f3cdeb59cdd10613c381f427adef0b6171fe1fe87156b2fc04d5 · Zeichen 1748–1893 im Abschnitt
Wechselwirkungen · Signifor
Signifor 0.3 mg solution for injection Signifor 0.6 mg solution for injection Signifor 0.9 mg solution for injection · Abschnitt 4.5 · PDF-Seite 6
HOS-213417 · Präparat HOS-155106
Bradycardic medicinal products
Clinical monitoring of heart rate, notably at the beginning of treatment, is recommended in patients
receiving pasireotide concomitantly with bradycardic medicinal products, such as beta blockers (e.g.
metoprolol, carteolol, propranolol, sotalol), acetylcholinesterase inhibitors (e.g. rivastigmine,
physostigmine), certain calcium channel blockers (e.g. verapamil, diltiazem, bepridil), certain
antiarrhythmics (see also section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): physostigmine (HOS-213421) diltiazem (HOS-086288) rivastigmine (HOS-087786) sotalol (HOS-085597) bepridil (HOS-085612) carteolol (HOS-213418) calcium (HOS-085615) propranolol (HOS-084529) acetylcholinesterase (HOS-213420) metoprolol (HOS-090094) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-12-18T10:26:00Z · SHA-256 8d39a4369995f88230d9c38d5acd5d8dc8ac03b6669b211c0130be10866c5ae6 · Passage 64ff24a4f7929c38dc46ad6f30004319ecfc5f654c3c1b6a8f5a890f3140972c · Zeichen 1483–1949 im Abschnitt
Wechselwirkungen · Signifor
Signifor 10 mg powder and solvent for suspension for injection Signifor 20 mg powder and solvent for suspension for injection Signifor 30 mg powder and solvent for suspension for injection Signifor 40 mg powder and solvent for suspension for injection Signifor 60 mg powder and solvent for suspension for injection · Abschnitt 4.5 · PDF-Seite 21
HOS-213450 · Präparat HOS-155106
Bradycardic medicinal products
Clinical monitoring of heart rate, notably at the beginning of treatment, is recommended in patients
receiving pasireotide concomitantly with bradycardic medicinal products, such as beta blockers (e.g.
metoprolol, carteolol, propranolol, sotalol), acetylcholinesterase inhibitors (e.g. rivastigmine,
physostigmine), certain calcium channel blockers (e.g. verapamil, diltiazem, bepridil), certain
antiarrhythmics (see also section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): physostigmine (HOS-213421) diltiazem (HOS-086288) rivastigmine (HOS-087786) sotalol (HOS-085597) bepridil (HOS-085612) carteolol (HOS-213418) calcium (HOS-085615) propranolol (HOS-084529) acetylcholinesterase (HOS-213420) metoprolol (HOS-090094) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-12-18T10:26:00Z · SHA-256 8d39a4369995f88230d9c38d5acd5d8dc8ac03b6669b211c0130be10866c5ae6 · Passage 64ff24a4f7929c38dc46ad6f30004319ecfc5f654c3c1b6a8f5a890f3140972c · Zeichen 1540–2006 im Abschnitt
Gegenanzeigen · Efavirenz Teva
Efavirenz Teva 600 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 3
HOS-215247 · Präparat HOS-155418
Co-administration with terfenadine, astemizole, cisapride, midazolam, triazolam, pimozide, bepridil,
or ergot alkaloids (for example, ergotamine, dihydroergotamine, ergonovine, and methylergonovine)
because competition for CYP3A4 by efavirenz could result in inhibition of metabolism and create the
potential for serious and/or life-threatening adverse reactions [for example, cardiac arrhythmias,
prolonged sedation or respiratory depression] (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): methylergonovine (HOS-086155) cisapride (HOS-085610) bepridil (HOS-085612) ergot alkaloids (HOS-108807) pimozide (HOS-085600) astemizole (HOS-085608) ergotamine (HOS-086154) terfenadine (HOS-085607) ergonovine (HOS-086153) triazolam (HOS-086168) dihydroergotamine (HOS-086152) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-03-03T18:18:00Z · SHA-256 d2c4a637bb18ba1e0c98c69218ce14671957659a5aa55fba40e74b1bf5620382 · Passage d2843e281aca9225d08f07c10f3d99b4761f6b40319a43fadd246a3dddbeab6a · Zeichen 174–636 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.